JZP-258

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Narcolepsy With Cataplexy

Conditions

Narcolepsy With Cataplexy

Trial Timeline

Mar 14, 2017 โ†’ Jul 10, 2019

About JZP-258

JZP-258 is a phase 3 stage product being developed by Jazz Pharmaceuticals for Narcolepsy With Cataplexy. The current trial status is completed. This product is registered under clinical trial identifier NCT03030599. Target conditions include Narcolepsy With Cataplexy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04794491ApprovedCompleted
NCT03030599Phase 3Completed

Competing Products

20 competing products in Narcolepsy With Cataplexy

See all competitors
ProductCompanyStageHype Score
E2086 + E2086 Placebo + Active Comparator + Active Comparator PlaceboEisaiPhase 1
33
MK-6552 + PlaceboMerckPhase 1
33
Sodium Oxybate (Xyrem)UCBPhase 1
30
JZP-110 + PlaceboJazz PharmaceuticalsPhase 2
49
ADX-N05 + PlaceboJazz PharmaceuticalsPhase 2
49
XyremJazz PharmaceuticalsPhase 3
74
JZP258Jazz PharmaceuticalsApproved
82
ADX-N05 + PlaceboJazz PharmaceuticalsPhase 2
49
Xyrem (sodium oxybate) oral solutionJazz PharmaceuticalsPhase 3
74
JZP-258Jazz PharmaceuticalsApproved
82
JZP441 + Matching PlaceboJazz PharmaceuticalsPhase 1
30
Xyrem + Xyrem Placebo + Modafinil at established dose + Modafinil (Placebo)Jazz PharmaceuticalsPhase 3
74
JZP-110 + Placebo oral tabletJazz PharmaceuticalsPhase 3
74
Transition from Xyrem to XywavJazz PharmaceuticalsPre-clinical
20
JZP-110Jazz PharmaceuticalsPhase 3
74
Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulantsAxsome TherapeuticsPre-clinical
20
AXS-12 (reboxetine) + PlaceboAxsome TherapeuticsPhase 3
74
Solriamfetol 150 mg Oral TabletAxsome TherapeuticsPhase 1
30
AXS-12 (Reboxetine) + PlaceboAxsome TherapeuticsPhase 2
49
AXS-12 (reboxetine) + PlaceboAxsome TherapeuticsPhase 3
74